Split History
ETFs Holding CLRB »    CLRB Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cellectar Biosciences is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co.'s lead phospholipid drug conjugate (PDC) therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. Co.'s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis (cell division) a validated pathway for treating cancers. According to our CLRB split history records, Cellectar Biosciences has had 2 splits.
CLRB split history picture
Cellectar Biosciences (CLRB) has 2 splits in our CLRB split history database. The first split for CLRB took place on March 07, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of CLRB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. CLRB's second split took place on July 17, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of CLRB owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 10 share position following the split.

When a company such as Cellectar Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CLRB split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cellectar Biosciences shares, starting with a $10,000 purchase of CLRB, presented on a split-history-adjusted basis factoring in the complete CLRB split history. CLRB split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/14/2011
End date: 04/13/2021
Start price/share: $140.00
End price/share: $1.40
Dividends collected/share: $0.00
Total return: -99.00%
Average Annual Total Return: -36.89%
Starting investment: $10,000.00
Ending investment: $99.97
Years: 10.01
Date Ratio
03/07/20161 for 10
07/17/20181 for 10
CLRB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CLRBW Split History
CLSN Split History
CMD Split History
CMN Split History
CNC Split History
CNDO Split History
CNMD Split History
COO Split History
COV Split History
CRDC Split History

Also explore: CLRB shares outstanding history

Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CLRB Insider Buying

CLRB Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.